About tango therapeutics inc - TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.
TNGX At a Glance
Tango Therapeutics, Inc.
201 Brookline Avenue
Boston, Massachusetts 02215
| Phone | 1-857-320-4900 | Revenue | 62.38M | |
| Industry | Biotechnology | Net Income | -101,594,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 48.29% | |
| Fiscal Year-end | 12 / 2026 | Employees | 137 | |
| View SEC Filings |
TNGX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.498 |
| Price to Book Ratio | 3.479 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.598 |
| Enterprise Value to Sales | 11.529 |
| Total Debt to Enterprise Value | 0.047 |
TNGX Efficiency
| Revenue/Employee | 455,357.664 |
| Income Per Employee | -741,562.044 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.169 |
TNGX Liquidity
| Current Ratio | 16.318 |
| Quick Ratio | 16.318 |
| Cash Ratio | 15.848 |
TNGX Profitability
| Gross Margin | 96.344 |
| Operating Margin | -178.393 |
| Pretax Margin | -162.846 |
| Net Margin | -162.853 |
| Return on Assets | -27.497 |
| Return on Equity | -37.235 |
| Return on Total Capital | -26.753 |
| Return on Invested Capital | -33.279 |
TNGX Capital Structure
| Total Debt to Total Equity | 9.697 |
| Total Debt to Total Capital | 8.84 |
| Total Debt to Total Assets | 8.188 |
| Long-Term Debt to Equity | 8.906 |
| Long-Term Debt to Total Capital | 8.119 |